



UNIVERSITY of MARYLAND  
SCHOOL OF MEDICINE



# **Establishing an Integrated Care Clinic for HCV-infected People Who Actively Inject Drugs at a Harm Reduction Center in Washington, DC (The ANCHOR Model)**

---

**Rachel Silk, RN, BSN, MPH, CCRC®** Gross C, Eyasu R,  
Sternberg D, Bijole P, Keir R, Jones M, Nussdorf L, Brokus C,  
D'Amore A, Mathur P, Kattakuzhy S, Rosenthal E

# Financial Disclosures

---

- **Drs. Kattakuzhy, Mathur and Rosenthal receive investigator grants to the University of Maryland, Baltimore from Gilead Sciences, Inc. and Merck.**

# Background

---

**People who inject drugs (PWID) have high rates of HCV acquisition but limited access to treatment**

**Recent studies have demonstrated high rates of SVR using direct acting antivirals (DAA) in PWID**

**Reduce HCV transmission and improve long-term outcomes for PWID**

- **Improve access to treatment**
- **Reduce harms associated with injecting drug use**

# Established Embedded Integrated Medical Care Clinic

---

- Partnered with HIPS, a harm reduction organization/drop-in center in Washington, DC




# **Four Key Components to Clinic Model**

---

- Culturally competent environment**
- Low-barrier medical care**
- Collocation of services**
- Community health workers**

# ANCHOR Study Schema




# Demographics

---


	Total Cohort n=100
<b>Median Age, years (IQR)</b>	56 (53-62)
<b>Men, n (%)</b>	76 (76)
<b>Black race, n (%)</b>	93 (93)
<b>Unstably housed, n (%)</b>	51 (51)
<b>Prior incarceration, n (%)</b>	92 (92)
<b>Injects opioids daily or more, n (%)</b>	59 (59)

# Visit Adherence and HCV Medication Dispensation





# Uptake of OAT, PrEP, and Naloxone



# Conclusions

---

- **Low-barrier medical clinic facilitated high uptake of HCV treatment, OAT, naloxone and moderate uptake of PrEP in a highly marginalized population**
- **Models of care aimed at providing culturally competent, integrated care are essential for eliminating HCV while addressing overall health in PWID**

# Acknowledgments

---

## ■ DC Partnership for HIV/AIDS

### Progress

- Rahwa Eyasu, NP
- Ashley Davis, NP
- Elana Rosenthal, MD
- Sarah Kattakuzhy, MD
- Poonam Mathur, D0
- Jasmine Stevens, BA
- Laura Nussdorf, BA
- Julia Mount, BA
- Christopher Brokus, BA
- Callie-Taylor Chandler

## ■ HIPS Staff

- David Sternberg
- Phyllis Bijole
- Miriam Jones
- Randy Kier

## ■ NIH

- Henry Masur, MD
- Carl Diffenbach, PhD
- Michael Polis, MD, MPH
- Elizabeth Akoth, RN

## ■ Institute of Human Virology, University of Maryland,

- Shyam Kottlil, MD, PhD
- Amy Nelson, RN
- Jenny Hoffman, NP
- Eleanor Wilson, MD
- Lydia Tang, MD
- Angie Price, NP

## ■ Funding support

- R01 DA043396-01A1 NIDA
- HHSN269201400012C, Office of AIDS Research/CCMD/CC/NIH
- Gilead Sciences – drug donation and investigator initiated research funding

*Special thank you to the patients*

# **More data on the ANCHOR Study at INHSU 2019**

---

## **■ Posters:**

**#056 – HCV Reinfection not Associated with OAT Engagement, Drug Use or Sexual Risk in Persons with Opioid Use Disorder and Injection Drug Use: Data from the ANCHOR study**

**#067 – High Uptake of Collocated Opioid Agonist Therapy with DAA is Associated with Reduced Risk and Improved SVR in People with Active Injecting Drug use: Data from the ANCHOR Study**

## **■ Oral Presentation on Friday:**

**Session V: High Rates of Opioid Overdose and Witnessed Overdoses in PWID Receiving HCV Treatment: Data from the ANCHOR Study**